EMERYVILLE, CA, RegCell, a biotechnology company developing first-in-class therapies to restore immune tolerance, has announced the closing of a fully subscribed Series A financing.
Continue Reading
Sign up for FREE to read the full article and access 159K+ alternative investment headlines.